In India, cervical cancer (CC) is the second most frequent cancer in women. It attributes 1/4 th (122,844 new cases) of the worldwide incidence of 528,000 new cases, and 67,477 deaths of a total of 266,000 deaths worldwide annually. [1, 2] Scientific literature has proved beyond doubt of the etiological role of 14 HR-HPV genotypes, namely HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 from around 200 different genotypes identified so far in causing CC and precursor lesion. [3] Prevalence and distribution pattern of HR-HPV genotypes vary in different geographical region and population. [3] Conventional Papanicolaou test, although still a recognised primary screening test, the limited sensitivity, subjective interpretation, low predictive value Background: Identification of 14 high-risk human papillomavirus (HR-HPV) is immensely important in elucidating molecular epidemiology, patient monitoring and evidence-based treatment. There is paucity of such data from Chhattisgarh state of Central India. The present study has evaluated tagging oligonucleotide cleavage and extension-mediated Anyplex HR-HPV genotyping assay in identification of 14 HR-HPV genotypes attributable to premalignant and malignant cervical lesion in comparison to GP5+/6+ assay, cytology and colposcopy. Materials and Methods: A total of 185 clinically suspected cases of premalignant and malignant cervical lesion were investigated by HR-HPV genotyping, GP5+/6+, cytology and colposcopy. Results: Genotyping assay showed clinical sensitivity and specificity of 86.5% (confidence interval [CI]: 80.7-91.0) and 100% (CI: 86.3-100) respectively and found noninferior to GP5+/6+ assay (P > 0.05). HR-HPV prevalence was 76.3%, 88.4%, 94.8%, 100% and 100% among cervical intraepithelial neoplasia (CIN) Grade I-III, squamous cell carcinoma and adenocarcinoma cases, respectively. The four most common genotypes detected in CIN I-III were HPV 16 (63.9%), HPV 39 (15.0%), HPV 18 (6.0%) and HPV 33 (5.3%). In cervical cancer (CC) cases, HPV 16 (44.4%), HPV 39 (11.1%), dual infection of HPV 16, 18 (11.1%) and triple infection of HPV 16, 18, 33 (11.1%) were the four most identified genotypic aetiologies. A novel coinfection of HR-HPV 35, 39 were found in two and one cases of CIN I and II. Finding of HPV 39 as the second most prevalent genotype was unusual and underscores the importance of genotyping screening. Conclusion: Anyplex HR-HPV assay is arguably the useful assay for better patient management and can be useful for HR-HPV screening by its unique individual genotype identification of all HR-HPV. Finding of HPV 16, 39, 18, 33 and coinfection of 16,18 and 16, 18, 33 in CIN and CC would help vaccine manufacturer to design specific future HPV polyvalent vaccine preparation to curb down the CC-associated mortality.
and providing only finding of cytologic abnormality with no information on HPV infection well augur for the utmost need of HPV genotyping test to provide the identification of causative HPV genotype responsible for premalignant and malignant cervical lesion. [3, 4] HPV genotypic information in the various stages of infection, clearance and persistence plays a significant role in patient monitoring and treatment by significantly helping gynaecologist in predecision for proper management before these lesions undergo invasive changes. [5] Various molecular assay based on real-time polymerase chain reaction (Real-time -PCR) have been available for HR-HPV genotyping. Widely accepted primer set targeting relatively conserved nucleotide sequences are GP5+/6+, MY09/11 and SPF 10. [6, 7] Due to multifactors, namely high cervical incidence in India, involvement of HR-HPV in persistent cervical lesion/infection leading to transformation of premalignant lesion to malignant lesion and geographical variation of HPV genotypes, it is of paramount importance to understand the insight of the prevalence of HPV genotype in all regions of the country. To best of our knowledge, no study has been published detailing genotypic distribution of HR-HPV from Chhattisgarh state of Central India. Chhattisgarh is located in the centre east of the country with a population of around 25,545,198 and female population of 12,712,303. The various published Indian studies so far has provided the information on HPV genotype circulation from various states such as Andhra Pradesh, Karnataka, Maharashtra, Tamil Nadu, Delhi, Tamil Nadu, West Bengal, Haryana, Manipur, Sikkim and Uttar Pradesh. [1, [8] [9] [10] Recently, a multiplex real-time PCR based on tagging oligonucleotide cleavage and extension (TOCE) chemistry, a proprietary technology of Seegene Inc, Seoul, Korea, has been developed to provide the significant advantage of allowing simultaneous individual detection and genotyping of 14 HR-HPV, namely 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 (L1 gene) and an internal control (human beta globin) in a single reaction. [11, 12] The TOCE technology has not yet been evaluated in Indian geographical conditions inhabited with different ethnic population.
This study was accordingly undertaken to identify HR-HPV genotype prevalence by HR-HPV genotyping Annyplex II assay (Seegene Inc., Seoul, Korea) and its evaluation against standard reference assay of HPV group-specific GP5+/GP6+ Polymerase Chain Reaction (PCR) followed by sequencing in women affected with premalignant (CINI-III) and malignant (SCC and AC) cervical lesions. Genotyping and GP5+/6+ assay were also compared with cytology and colposcopy. These patients represented a heterogeneous group of women from different ethnic background predominated by tribals having different economic, sociodemographic and cultural backgrounds whose HPV genotyping has not been described previously and who are considered to be a vulnerable population having limited access to healthcare services.
MaterialS and MethOdS

Patients and clinical samples
From 1 st September 2017 to 3 rd September 2018, a total of 185 clinical samples of cervical scrapes from ectocervix and endocervix region containing exfoliated epithelial cells were obtained on cervical brush in 1X phosphate-buffered saline (PBS) (pH 7.2) by Gynaecologist from equal number of suspected women of 21-65 years age group. These patients had cervix suspicious of premalignant (158, 85.4%) or malignant lesion (27, 14%) based on clinical examination and visual inspection of uterine cervix after application of 5% acetic acid (VIA) and/or of Lugols iodine (VILI). The following inclusion and exclusion criteria were used.
Inclusion criteria
1. Ulcerative cervical lesion or growth 2. Positive VIA or VILI or both 3. No history of HPV vaccination.
Exclusion criteria
1. Normal looking cervix 2. Negative for VIA and VILI 3. Pregnancy 4. Any history of cervical surgery or hysterectomy 5. Any intravaginal medication or suppository within last 7 days of sampling 6. HPV vaccination history.
Their demographic details are shown graphically [ Figure 1 ]. In addition, 25 women having a normal cervix on both clinical examination including VIA/VILI, colposcopy and cytology (Pap) smear examination were also included as control group. Institutional ethical approval (AIIMSRPR/ IEC/2017/095) and written informed consent were obtained from all the patients and control group in a predesigned consent form. All the clinical samples were divided into two parts with first sent to the pathology and second to the microbiology department of All India Institute of Medical Sciences (AIIMS), Raipur for cytology and HPV genotyping, respectively. All the patients were classified in four age groups of 25-34 years, 35-44 years, 45-54 years 
PAP smear examination
Cytology results were read as per Bethesda 2001 directive and classified into atypical squamous cells of undetermined significance (ASCUS), atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion (ASCH), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), negative for intraepithelial lesion or malignancy (NILM) and invasive carcinoma (SCC and AC). [13] 
Colposcopy
Colposcopic finding of changes such as acetowhite epithelium, dotted, mosaic, partial iodine positive epithelium and iodine negative epithelium were classified as positive colposcopy as per the European guidelines. [14] 
Classification of cervical lesion
Colposcopy Reid score and cytology were used to classify cervical intraepithelial neoplasia (CIN I to CIN III), SCC and AC.
DNA extraction
HPV DNA was isolated using QIAmp DNA minikit (QIAgen, Germany) with slight modification to manufacture instruction. 1 ml of PBS medium containing cytobrush was briefly vortexed to dislodge exfoliated cervical epithelial cells and then separated in 1.5 ml microcentrifuge tube. It was centrifuged for 10 min at 14000 rpm and 200 µl of sample from bottom portion were digested with 20 µl Proteinase K and 200 µl lysis buffer AL and kept the suspension at 56°C for 30 min with rest of the procedure as per the instruction provided in the kit.
β-globin, GP5+/GP6+, PCR and sequencing
The PCR assays simultaneously amplified 110 bp sequence of β-globin gene using primer sequence o f 5 ' -A C A C A A C T G T G T T C A C TA G C -3 ' a n d 5'-CAACTTCATCCACGTTCACC-3' and 150 bp conserved sequence from L1 gene with the primers sequence of GP5+ (5'-TTTGTTACTGTGGTAGATACTAC-3') and GP6+ (5'-GAAAAATAAACTGTAAATCA-3') as described earlier. [15] The 150 bp GP5+/6+ amplicons were purified and sequenced in ABI 3130 sequencer (ABI, USA) as described in one of our earlier study. [16] The sequences were subsequently analysed using online NCBI BLAST server (http://www.ncbi. nih.gov/BLAST/) to confirm genotype.
HR-HPV Anyplex II genotyping assay
It was performed according to the manufacturer's instruction using CFX 96 real-time thermocycler (BioRad, Hercules, California) to amplify HPV L1 gene for genotyping and human β globin to assess cell adequacy and PCR inhibition. Principally, it is a multiplex PCR reaction which works on template based melting temperature instead of the current probe-based melting temperature and distinguishes multiple targets in a single channel in a real-time PCR reaction. [12] The TOCE technology of the HR-HPV is initiated with hybridisation of the dual priming oligonucleotide primers and the 'Pitcher' to the target sequence. Taq polymerase with 5'-nuclease activity encounters the target bound Pitcher and releases the tagging portion of the Pitcher. The sequence of the released tagging portion is complementary to the capturing portion of the 'Catcher' as an artificial template. As the tagging portion is fully extended on the Catcher to create the 'Duplex Catcher', quenching is diminished and the fluorescent signal can be detected. Approximate time from processing of clinical samples and analysis was 6 h. Detection limit claimed was 50 HPV copies/reaction.
Statistical analysis
SPSS version 15.0 software (SPSS Inc., Chicago, IL, USA) was used for statistical analysis using Chi-square (χ 2 ) test. P < 0.05 was considered as statistically significant.
reSultS
The age group of 35-44 years was significantly observed with maximum number of cases (n = 83, 44.8%) followed by the age group of 45-55 years (n = 48, 25.9%), 25-34 years (n = 47, 25.4%) and 56-65 years (n = 07, 3.7%) (χ 2 = 1.43, P < 0.05) [ Table 1 ]. Even on age-wise categorisation of premalignant and malignant CC cases, the mild, moderate and severe dysplasia (CIN I-III) were found maximally in the age group of 35-44 years whereas SCC and AD have mainly been seen in 45-55 years age strata. CIN I was found in predominance (76/185, 41.08%) in comparison to CIN II (43/185, 23.24%) and CIN III (39/185, 21.08%) category. The affected mean age was calculated as 39.4 years + standard deviation (SD) 8.94 (data not shown).
A total of 185 cervical scrape samples from equal number of cases were tested by cytology and molecular tests of GP5+/6+ PCR and Anyplex II genotyping assay.
Cytology detected 95 cases of premalignant and malignant CC with sensitivity of 51.3% (CI 43.9-58.7) [ Table 1 ]. These 95 cases comprised of 68 cases of CIN I-III (20 CIN I, 21 CIN II, 27 CIN III) and 27 cases of CC (21 SCC and 06 AC), respectively. HPV GP5+/6+ PCR showed the maximum detection of HPV in 170 cases by Table 1 and Figure 3 ]. The internal control of specific amplification of 110 bp region of human β-globin gene showed appropriate DNA integrity/adequacy and absence of PCR inhibitors [ Figure 3 ]. Anyplex II HPV genotyping on the other hand identified 14 HR-HPV in 160 cases claiming sensitivity of 86.5% (CI 80.7-91.1). Colposcopy revealed sensitivity of 68.1% (CI 60.8-74.7). Although among all the tests, GP5+/6+ PCR showed significant high sensitivity (χ 2 = 29.4, P = 0.000034), its inability to differentiate the HPV into the level of individual identification of 14HR-HPV till further processed by nucleotide sequencing and subsequent NCBI nucleotide BLAST identification has limited its widespread use in screening of CC. On intertest comparison, significant difference was found when HPV GP5+/6+ assay and HPV genotyping were individually compared against cytology, respectively (χ 2 = 22.12, P = 0.00019 and χ 2 = 26.3354, P = 0.000027, P < 0.05). However, on individual comparison with colposcopy, none of the PCR showed any significant difference (P > 0.05) as GP5+/6+ assay showed values of χ 2 = 3.3399, P = 0.502369 and HPV genotyping showed χ 2 = 1.7952, P = 0.773366. On comparison of the two PCR assay, although GP5+/6+ showed higher sensitivity of 91.9% in comparison to HPV genotyping (86.5%), the difference was not found significant (P > 0.05) (χ 2 = 0.3583, P = 0.9857). HPV genotyping has identified the presence of 14 HR-HPV in 160 cases (86.5%), and these results were further confirmed by sequencing of GP5+/6+ amplicons [ Figure 4 ]. HPV genotyping could not be determined in GP5+/6+ detected 9 CIN I and 1 CIN II cases. Sequencing of their GP5+/6+ amplicons has confirmed the presence of low-risk HPV genotype 28, 32, 54 and 55 in 3, 2, 1 and 4 cases, respectively (data not shown). Interestingly, all the four tests employed in the study showed 100% positivity in all cases of SCC and AC. In various CIN category, HPV genotyping although showed identical positivity to GP5+/GP6 + of 94.9% (CI 82.7-99.4) in severe dysplasia (CIN III), it showed slightly low positivity of 80.7% (96/119) in mild and moderate dysplasia (CIN I, 76.3% and CIN II, 88.4%) in comparison of 89.1% by GP5+/6+ (CINI 88.2% and CIN II 90.7%) assay (χ 2 = 0.1663, P > 0.05). Colposcopy and cytology also showed the same pattern of results albeit with gradual decrease in positivity/detection rate from CIN III to CIN I [ Table 1 ]. In 25 control biopsy samples, none of the tests showed false positivity, thus showed 100% specificity. GP5+/6+ group assay showed sensitivity, specificity, positive predictive value and negative predictive value of 98.7%, 100%, 100% and 96.2% whereas these figures for HPV genotyping were calculated to 96.1%, 100%, 100% and 89.3%, respectively. Overall agreement between genotyping and GP5+/6+ assay was 94.1% with a k value of 0.94 (95% CI, 89.5-97.1). The overall prevalence of HR-HPV in premalignant and malignant CC was 84.1% and 100%, respectively (P > 0.05).
On individual comparison with cytology, GP5+/6+ and HPV genotyping showed 100% positivity by detecting HPV in all cases of SCC, AC, ASCH and ASCUS [ Figure 5 ]. Cytology confirmed one HSIL, and two LSIL cases were not identified by HPV genotyping. Thus, overall HPV genotyping detected 96.8% (92/95, CI 91.0-99.3) prevalence of HR-HPV in cytology-confirmed positive cases.
On identification and distribution pattern of 160 HR-HPV cases, 91.9% cases had only one HPV genotype whereas 8.1% had more than one HPV genotype aetiology [ Table 2 ]. In CIN I-III, 96.2% samples showed HPV monotype whereas 3.8% showed multiple genotypes. In CC, 70.4% showed HPV monotype whereas 29.6% showed multiple genotypes. HPV genotype 16 was the most prevalent with 66.9% cases (97 monotype and 10 coinfection) [ Table 2 ]. This was followed by HPV genotype 39 with 16.3% prevalence (23 monotype and 3 coinfection), HPV genotype 18 (10%, 9 monotype and 7 coinfection), HPV 33 (7.5%, 8 monotype and 4 coinfection), HPV 59 (3.8%, 4 monotype and 2 coinfection), HPV 68 (1.9%, 3 monotype), HPV 52 (1.3%, 2 monotype) and HPV 45 (0.6%, 1 monotype), respectively. Coinfection of more than one genotype was found in 8.1% (13/160) cases with 61.5% (8 cases) found in CC and 38.5% in collective CIN. In invasive carcinoma, HPV 16 was found as the sole etiological agent in 9 cases of SCC and 3 cases of AC in addition to its presence also found in coinfection with one or more genotypes (7 cases in SCC and 1 case in ACC) with a total prevalence of HPV 16 found to be 76.2% in SCC and 66.7% in AC. The second most predominant HPV genotype detected in SCC was HPV 18 with prevalence of 28.5%. However, HPV 18 was found mainly as coinfection along with HPV 16 as evident from seven CC cases (6 SCC and 1 AC case), and single aetiology of HPV 18 was observed in only one case of SCC. HPV 39 was found associated in single aetiology factor in two case of SCC and one case of AC [ Table 2 ].
diScuSSiOn
Specific information on prevailing HR-HPV genotype aetiological cause of CIN, SCC and AC is not only useful for treatment but also of paramount importance in promulgating various strategies on screening, treatment, research and manufacturing of specifically designed multivalent vaccine to provide immunity against all or specifically predominantly circulating genotypes which would eventually help in reducing the CC incidence and mortality.
We have found higher sensitivity of HPV genotyping in comparison to cytology and colposcopy. HPV genotyping fulfilled the international criteria of demonstrable sensitivity for CIN Grade 2 or 3 and treatable cancer of 0.90 or greater and specificity for CIN 2+ of 0.98 or greater. [5] Slightly lower sensitivity of HPV genotyping in comparison to GP5+/6+ could be due to type-specific identification of 14 HR-HPV rather than targeting broad-spectrum HPV by GP5+/6+. Moreover, GP5+/6+ assay has limited clinical utility because it does not reveal identity of any specific genotype until processed for sequencing as seen in the present study. Even some studies have preferred MY09/11 over GP5+/6+ for sequencing due to large amplicon size of 450 bp with MY09/11 than 150 bp of GP5+/6+. [17] Hence, detecting broad-spectrum HPV in the clinical samples may not provide any specific information of whether the detected HPV belongs to nonrelevant group or high-or low-risk group and eventually keeping both the molecular biologist and clinician in a loop/lurch leading to obvious delay in the decision on treatment strategy. We have found 100% prevalence of HR-HPV in SCC and AC cases and 73.4% in premalignant cervical lesions. The prevalence of HR-HPV found varied among various studies. Anderson et al. [18] detected 92.2% HPV prevalence in SCC and 68% across all cervical samples investigated. In Chennai, 99.4% HPV prevalence was detected in invasive cervical samples. [19] Sowjanya et al. [8] found 87.8% HR-HPV prevalence in invasive SCC. The low positivity obtained in Sowjanya et al. study could be due to DNA degradation in some of the samples leading to false-negative results using PGMY 09/11 consensus primers. The increasing detection rate of 76.3%, 88.4%, 94.9% and 100% in mild (CIN I), moderate (CIN II) and severe (CIN III) cases of dysplasia and CC was also found in line of earlier studies to sufficiently endorse the fact of etiological role of HR-HPV in progression of cervical neoplasia/dysplasia, and hence, early detection of HR-HPV decisively provide better prognosis and management and thus can be mandatorily added to the list of HPV screening tests. [18] The affected mean age was found 39.4 years + SD 8.94. Between various affected age groups, age group of 35-44 years was found most affected for CIN I-III whereas age group of 45-55 years with SCC and AC. Basu et al. [20] showed age group of 40-59 years as most affected with CC. Sowjanya et al. [8] showed maximum number of patients in 36-40 years strata. Anderson et al. [18] showed affected mean age group of 32 years + SD 9.4 and CIN I-III maximally in age group of up to 29 years and SCC in women of age group 35-39 years. However, our results were quite in contrast to the earlier published study of Sreedevi et al. [1] who has found 55-59 years as the peak age of incidence of CC whereas we found only 7 cases in ≥56 years category. The probable reason for different susceptible age group among various studies could be due to variation in demographic and sociocultural profile of the population being studied which however would require a further mass epidemiological studies to endorse these reasons.
On frequency of HPV genotype distribution, we too found predominant involvement of single HPV genotype (91.9%) than coinfection with multiple HPV genotype (8.1%) and HPV genotype 16 as most frequent HPV genotype in line with earlier published studies. [18] The higher monotype percentage in both CIN and CC arguably indicated a role of persistent infection of at least one HR-HPV in progression of cervical lesion from premalignant to malignant lesion. However, the second most frequent genotype found in our study was HPV 39 (18.25%) instead of usual HPV genotype 18 (10.2%). Franceschi et al. [19] reported HPV 42 as the second most common detected HPV genotype. Our finding of HPV 39 as the second most prevalent genotype reiterated the fact that HPV genotype circulation varies according to ethnicity and geographical condition. A meta-analysis by Bhatla et al. [21] showed HPV 16 and 45 more prevalent in North India, while HPV 16 and 35 have higher prevalence in South India. In China and Mexico, HPV genotype 52 was found as the second most predominant genotype. [22, 23] In SCC and AC, HPV 16 showed 76.2% (16/21) and 66.7% (4/6) prevalence in monotype aetiology, respectively. In multitype aetiology too, HPV 16 was found in eleven (68.7%) of sixteen cases. HPV 39 was found more prevalent than HPV 18 in monotype aetiology whereas HPV 18 detected more while considering both monotype and multitype aetiologies in both SCC and AC cases, respectively. The four most commonly detected HPV genotypes were 16, 39, 18 and 33 in CIN I-III whereas HPV 16, dual infection of 16, 18, triad of 16, 18, 33 and monotype infection of HPV 39 were the most common genotype detected in SCC. In AC, monotype infection of HPV 16, 39, 52 and coinfection by 16, 18 and 33 were only found. HPV 16 dominated also in mixed infection and give reasonable argument of its presence as predisposing factor for colonisation by other HR-HPV genotypes. Basu et al. [20] showed HPV 16, 18, 31 and 33 in SCC and AC with overall HR-HPV prevalence of 92.7% and 81.8% in SCC and AC, respectively. In one of the prospective studies from Delhi, the highest frequency rate of persistence was found in order of HPV genotype 16, 59, 52 and 18. [9] Coinfection of HPV 35 and 39 was found as unusual and unreported in mild or moderate CIN.
On comparison with cytology, HPV genotyping detected 96.8% abnormal cytology cases. It confirmed all cases of SCC, AC, ASCH and ASCUS. The main advantage over cytology was observed in NILM cases where 75.6% (68/90) cases showed HPV aetiology. This high positivity was attributed mainly due to detection of HR-HPV in 87.5% inflammatory smears (63/72) and 27.7% (5/18) in normal cervical cytology. Senapati et al. [17] also observed high HPV prevalence of 54.3% in inflammatory smears and 19.1% in normal cervical cytology.
Anyplex HPV genotyping assay was also earlier evaluated in various countries. [5, 11] Hesselink et al. [11] found clinical sensitivity and specificity of 98.3% and 93.6%, respectively, for CIN2+ in women from Netherland. Jung et al. [5] found 94.4% and 92.5% sensitivity in HSIL and CIN II in Korean women.
The possible limitations of the present study were low number (06) of AC which could not adequately sufficient for analysis and reasonable conclusion on AC. Not covering every district of Chhattisgarh also leave a scope of more such study on larger scale by involving all primary, community and district health centres. Nevertheless, the result showed usefulness of HPV genotyping assay in early, rapid and accurate individual identification of all 14 HR-HPV genotype in both premalignant and malignant cases of CC for better patient management. cOncluSiOn Anyplex II HPV TOCE-based RT-PCR-mediated HPV genotyping assay represents a more sensitive methodology than cytology and colposcopy to identify CINI-III and CC and thus presents a strong case of its implementation in CC screening. Finding of HR-HPV genotype 16, 39, 18, 31, 68, 59, 52 and 45 may quest vaccine manufacturers/ researchers to prepare multivalent vaccine against these HPV genotypes to bring down the cancer cervix burden in Chhattisgarh, India. 
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